Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
BMC Cancer|June 5, 2019
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)A Carrato, M Benavides, B Massutí, et al.
Frontiers in Oncology|March 27, 2023
Cervical cancer prevention program in Mexico disrupted due to COVID-19 pandemic: Challenges and opportunitiesAurelio Cruz-Valdez, Lina Sofia Palacio-Mejía, Amado D Quezada-Sánchez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trialA Abad, E Martínez-Balibrea, J M Viéitez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2014
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancerM J Sotelo, J Sastre, M L Maestro, et al.
Cancer Chemotherapy and Pharmacology|December 11, 2014
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02F Rivera, B Massutí, M Salcedo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 4, 2017
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancerJ Grasselli, E Elez, G Caratù, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapyJ Vidal, B Bellosillo, C Santos Vivas, et al.
Clinical Colorectal Cancer|March 21, 2023
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized TrialsP Jiménez-Fonseca, J Sastre, P García-Alfonso, et al.
European Journal of Cancer (Oxford, England : 1990)|May 1, 1996
A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapyB Audhuy, P Cappelaere, M Martin, et al.
ESMO Open|November 28, 2024
Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trialP García-Alfonso, E Elez, J Soto-Alsar, et al.
Pageof 21